Arrowhead Pharmaceuticals (ARWR) Leases (2016 - 2025)
Arrowhead Pharmaceuticals (ARWR) has disclosed Leases for 16 consecutive years, with $43.4 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Leases fell 3.36% year-over-year to $43.4 million, compared with a TTM value of $43.4 million through Dec 2025, down 3.36%, and an annual FY2025 reading of $43.9 million, down 3.01% over the prior year.
- Leases was $43.4 million for Q4 2025 at Arrowhead Pharmaceuticals, down from $43.9 million in the prior quarter.
- Across five years, Leases topped out at $96.3 million in Q2 2023 and bottomed at $16.4 million in Q1 2022.
- Average Leases over 5 years is $43.9 million, with a median of $43.9 million recorded in 2025.
- The sharpest move saw Leases surged 236.05% in 2022, then plummeted 53.98% in 2024.
- Year by year, Leases stood at $42.0 million in 2021, then increased by 0.1% to $42.0 million in 2022, then rose by 6.88% to $44.9 million in 2023, then dropped by 0.08% to $44.9 million in 2024, then fell by 3.36% to $43.4 million in 2025.
- Business Quant data shows Leases for ARWR at $43.4 million in Q4 2025, $43.9 million in Q3 2025, and $44.0 million in Q2 2025.